Colorectal cancer: Treatment of advanced disease

Cancer Treatment Reviews

Volumn 24, Issue 2, 1998, Pages 119-131

  Seymour, M T ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NITROSOUREA; OXALIPLATIN; PEMETREXED; PRODRUG; RALTITREXED; TEGAFUR; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; ALOPECIA; ANGIOGENESIS; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG INFUSION; DRUG TOXICITY; HEPATIC ARTERY; HUMAN; IMMUNOTHERAPY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LIVER METASTASIS; LIVER SURGERY; MEDICAL DECISION MAKING; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; RNA TRANSLATION; VOMITING;

EID: 0031716238     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90078-0     Document Type: Article

References (111)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46(1): 5-27.
2. Cancer Research Campaign. Cancer Statistics Factsheet 3.2-3, 1995.
3. Forman D, Rider L (eds). Cancer in Yorkshire - Cancer Statistics 1989-93. Yorkshire Cancer Organisation, 1996.
4. Hughes KS. Resection of the liver for colorectal carcinoma metastases - a multi-institutional study of indications for resection. Surgery 1988; 103(3): 278-288.
5. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg 1989; 210: 127-138.
6. Scheele J, Stand R, Altendorfhofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19(1): 59-71.
7. Adson MA. Resection of liver metastases - when is it worth-while? World J Cancer 1987; 11(4): 511-520.
8. Rougier P, Milan C, Lazorthes F et al. Prospective-study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82(10): 1397-1400.
9. Norstein J, Silen W. Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg 1997; 1: 398-407.
10. SSAT, AGA, ASLD, ASGE, AHPBA Consensus Panel. Treatment of hepatic metastases from colorectal cancer. J Gastrointest Surg 1997; 1: 396-397.
11. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: comparing the views of patients with cancer with those of doctors, nurses and the general public. Br Med J 1990; 300: 1458-1460.
12. Scheithauer W, Rosen H, Komet GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-755.
13. Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-274.
14. Beretta G, Bollina R, Cozzi C & Beretta A. Should we consider the weekly chemotherapy with fluorouracil plus racemic folinic acid a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients? Proc Am Soc Clin Oncol 1997; 16: 920.
15. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-911.
16. Hafstrom L, Engaras B, Holmberg SB et al. Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion and oral allopurinol. A randomized clinical trial. Cancer 1994; 74: 2749-2756.
17. Rougier P, Laplanche A, Huguier M et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomised trial. J Clin Oncol 1992; 10: 1112-1118.
18. Allen-Mersh TG, Earlam S, Fordy C, Abrams K & Houghton J. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-1260.
19. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G & Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75: 11-17.
20. Fountzilas G, Gossios K, Zisiadis A, Svarna E, Skarlos D & Pavlidis N. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Paediatr Oncol 1996; 26: 305-317.
21. ACCMP (Advanced Colorectal Cancer Meta-Analysis Project). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
22. ACCMP (Advanced Colorectal Cancer Meta-Analysis Project). Meta-analysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-969.
23. Leichman L, Lenz HJ, Leichman CG et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance for protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995; 31: 1306-1310.
24. Kornmann M, Link KH, Lenz HJ et al. Thymidylate synthase is a predictor of response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997; 118: 29-35.
25. Danenberg K, Metzger R, Groshen S et al. Thymidylate synthase and thymidine phosphorylase indications of survival for colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 914.
26. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 1995; 55(7): 1407-1412.
27. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A & Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997; 75: 903-909.
28. Aschele C, Casazza S, Debemardis D et al. Lack of correlation between p53 overexpression and response to Fura-based chemotherapy in advanced colorectal cancer patients. Proc Am Soc Clin Oncol 1997; 16: 916.
29. Schneider HJ, Sampson SA, Cunningham D et al. Bcl-2 expression and response to chemotherapy in colorectal adenocardnomas. Br J Cancer 1997; 75: 427-431.
30. Paradiso A, Rabinovich M, Vallejo C et al. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 1996; 69(6): 437-441.
31. Benson AB, Catalano PJ, Rao S et al. Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients with resected colon or advanced colorectal cancer. An ECOG study. Proc Am Soc Clin Oncol 1997; 16: 917.
32. Brett MC, Pickard M, Green B et al. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996; 22: 182-185.
33. Kobayashi M, Watanabe H, Ajioka Y, Yoshida M, Hitomi J & Asakura H. Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virchows Arch 1995; 427(1): 27-32.
34. Lennon T, Houghton J & Northover J. What is the value of clinical follow-up for colorectal cancer patients? The experience of the CRC/NIH CEA second-look trial. Nottingham International Colorectal Cancer Symposium, 1995.
35. Ohlsson B, Breland U, Ekberg H, Graffner H & Tranberg K. Follow-up after curative surgery for colorectal carcinoma. Randomised comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-626.
36. Makela J, Laitinen S & Kairaluoma M. Five-year followup after radical surgery for colorectal cancer. Results of a prospective randomised trial. Arch Surg 1995; 130: 1062-1067.
37. Seymour MT, Cassidy J, Stenning SP & Duffy AM, for the Colorectal Cancer Working Party of the UK Medical Research Council. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Clin Oncol 1997; 9: 248-251.
38. Medical Research Council (UK). Trial protocol CR06 - chemotherapy choices in advanced colorectal cancer. A randomised trial comparing 2 durations and 3 systemic chemotherapy regimens in the palliative treatment of advanced colorectal cancer. MRC Cancer Trials Office, Cambridge, UK, 1997.
39. Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. New Engl J Med 1987; 317: 1490-1495.
40. Catimel G, for ERASME Group. Comparison of continuous and discontinuous chemotherapy in patients with metastatic breast cancer: final analysis of a phase II randomised study. Ann Oncol 1992; 3(Suppl.5): 79.
41. Bleehen NM, Payers PM, Girling DJ & Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989; 59: 584-590.
42. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesmann MM & Pastan I. Expression of a multidrug resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
43. Danenberg PV & Danenberg KD. Effect of 5,10-methylene-tetrahydrofolate on the dissociation of fluoro-2′deoxyuridylate from thymdylate synthetase: evidence for an ordered mechanism. Biochemistry 1978; 17: 4018-4024.
44. Ingraham HA, Tseng BY & Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res 1980; 40: 998-1001.
45. Chu E, Lai GM, Zinn S & Allegra CJ. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 1990; 38: 410-417.
46. Chu E, Zinn S, Boarman D & Allegra CJ. Interaction of g interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990; 50: 5834-5840.
47. Chu E, Koeller DM, Casey JL et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991; 88: 8977-8981.
48. Moran RG, Keyomarsi K & Patel R. Tumour cell responses to inhibition of thymidylate synthase. Adv Exp Med Biol 1988; 244: 71-83.
49. Elias L & Sandoval. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989; 163: 867-874.
50. Greenhalgh DA & Parish JH. Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells. Cancer Chemother Pharmacol 1989; 25: 37-44.
51. Maybaum J, Ullman B, Mandel HG et al. Regulation of RNA-and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 1980; 40: 4209-4215.
52. Drewinko B & Yang L-Y. Cellular basis for the inefficacy of 5FU in human colon carcinoma. Cancer Treat Rep 1985; 69: 1391-1398.
53. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA & Fryer JG. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-432.
54. Hansen RM, Ryan L, Anderson T et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996; 88: 668-674.
55. Rougier P, Buyse M, Ryan L et al. Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 946.
56. Larsson PA, Carlsson G, Gustavsson B, Graf W & Glimelius B. Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. Acta Oncol 1996; 35: 207-212.
57. Levi FA, Zidani R, Vannetzel JM et al. Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomised multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-1617.
58. Levi F, Zidani R & Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-686.
59. Greco FA, Figlin R, York M et al. Phase III randomised study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 2674-2681.
60. Seymour M, Slevin M, Kerr D et al. Randomised trial assessing the addition of inteferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 1996; 14: 2280-2288.
61. Hill M, Norman A, Cunningham D et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1996; 13: 2317-2323.
62. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297-1302.
63. Corfu - A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995; 13: 921-928.
64. Laufman LR, Bukowski RM, Collier MA et al. A randomised, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993; 11: 1888-1893.
65. Blijham G, Wagener T, Wils J et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomised European Organisation for Research and Treatment of Cancer study. J Clin Oncol 1996; 14: 2266-2273.
66. Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomised phase III trial. Gastrointestinal Tumour Study Group. J Clin Oncol 1989; 7: 1419-1426.
67. Poon M, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectral cancer. J Clin Oncol 1991; 9: 1967-1972.
68. Buroker TR, O'Connell MJ, Wieand HS et al. Randomised comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20.
69. Jager E, Heike M, Bernhard H et al. Weekly high-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomised multicentre trial. Study Group of Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14: 2274-2279.
70. Labianca R, Cascinu S, Frontini L et al. High versus low dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a GISCAD phase III study. Italian Group for the study of digestive tract cancer. Ann Oncol 1997; 8: 169-174.
71. De Gramont A, Bosset JF, Milan C et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997; 15: 808-815.
72. Weh HJ, Wilke HJ, Dierlamm J et al. Weekly therapy with folinic acid and high dose 5-fluorouracil 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicentre study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994; 5: 233-237.
73. Gray R, James R, Mossman J & Stenning S. AXIS - a suitable case for treatment. Br J Cancer 1991; 63: 851-855.
74. Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ & Hohn DB. Hepatic arterial chemotherapy for colorectal cancer metastatic to liver. Ann Intern Med 1984; 100: 736-743.
75. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-258.
76. Medical Research Council (UK). Trial protocol CR05 - chemotherapy choices in colorectal cancer. A randomised trial of intravenous versus intrahepatic arterial 5-FU and leucovorin for colorectal liver metastases. MRC Cancer Trials Office, Cambridge, UK, 1994.
77. Anttila MI, Sotaniemi EA, Kaiaralcoma MI. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 1983; 10: 150-153.
78. Pazdur R, Covington WP, Brown NS, Lassere Y, Diaz-Canton E & Ho DH. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluouroucil. Proc Am Soc Clin Oncol 1996; 15: 1498.
79. Ota JM, Taguchi T & Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333-338.
80. Rustum YM, Cao S, Shirasaka T & Taguchi T. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II clinical trials. Proc Am Soc Clin Oncol 1997; 16: 799.
81. Findlay MP, van Cutsem E, Kocha W et al. A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 798.
82. Cunningham D, Zalcberg JR, Rath U et al. and the 'Tomudex' Colorectal Cancer Study Group. Final results of a randomised trial comparing 'Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-965.
83. Cripps MC, Burnelf M, Jolivet J et al. Phase II study of a multi-targeted antifolate (LY231514) as first-line therapy in patients with locally advanced or metastatic colorectal cancer. Prom Am Soc Clin Oncol 1997; 16: 949.
84. Loehrer PJ, Turner S, Kubilis P et al. A prospective randomised trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hosier Oncology Group trial. J Clin Oncol 1988; 6: 642-648.
85. Kemeny N, Israiel K, Niedzwieckid et al. Randomised study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with libitum colorectal cancer. J Clin Oncol 1990; 8: 313-318.
86. Lokich JJ, Ahlgren JD, Cantrell et al. A prospective randomised comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. Cancer 1991; 67: 14-19.
87. Scheithauer W, Depish D, Kornek G et al. Randomised comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer 1994; 73: 1562-1568.
88. Becouarn Y, Ychou M, Ducreux M et al. Oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: preliminary activity-toxicity report. Proc Am Soc Clin Oncol 1997; 16: 804.
89. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-98.
90. Pappamichael D, Joel SP, Seymour MT, Bowerbank M & Slevin ML. Pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Proc Am Soc Clin Oncol 1998; 17: 777.
91. De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-219.
92. De Gramont A, Figer A, Seymour MT, Homerin M, Le Ball N, Cassidy J, Boni C, Cortes-Funes H, Freyer G, Hendler D & Louvet C. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 1998; 17: 985.
93. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260.
94. Cunningham D, Pyrhonen S, James RD et al. A Phase III multicentre randomised study of CPT-11 versus supportive care alone in patients with 5FU-resistant metastatic colorectal cancer. Proc Am Soc Clin Oncol 1998; 17: 1.
95. Van Cursem E, Bajetta E, Niederle N et al. A phase III multicentre randomized trial company CPT-II to infusional 5FU regimen in patients with advanced colorectal cancer after 5FU failure. Proc Am Soc Clin Oncol 1998; 17: 984.
96. Moertel CG. Chemotherapy of gastrointestinal cancer. New Engl J Med 1978; 299: 1049-1055.
97. Richards F, Case LD, White DR et al. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol 1986; 4(4): 565-570.
98. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001.
99. IMPACT-International Multicentre Pooled Analysis of Colon Cancer Trials Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-944.
100. O'Connell M, Mailliard J, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250.
101. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887.
102. Primrose JN, Bleiberg H, Daniel F et al. Marimastat in recurrent colorectal cancer - exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 1998, in press.
103. Eckhardt SG, Burris HA, Eckhardt JR et al. A phase 1 clinical and pharmacokinetic study of the angiogenesis inhibitor tecogalan sodium. Ann Oncol 1996; 7: 491-496.
104. Reitmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343: 1177-1183.
105. Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11: 385-386.
106. Conry RM, Lobuglio AF, Loechel F et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995; 2: 33-38.
107. Chang AE, Cameron MJ, Sondak VK, Geiger JD & Vander Woude DL. A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma. J Immunother Emphasis Tumour Immunol 1995; 18: 253-262.
108. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622-632.
109. Martin J, Stribbling SM, Poon GK et al. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 1997; 40: 189-201.
110. Bookstein R, Demers W, Gregory R, Maneval D, Park J & Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23(1): 66-77 (review).
111. Zbar M, Leomine NR, Wadhwa M, Thomas H, Snary D & Kmiot WA. Biological therapy approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen as an immunological target. Br J Cancer 1998; 77: 683-693.